D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
NCT ID: NCT00237809
Last Updated: 2017-05-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
104 participants
INTERVENTIONAL
2002-09-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia
NCT00237848
D-serine for the Schizophrenia Prodrome
NCT00826202
D-serine and Cognitive Remediation in Schizophrenia
NCT02156908
D-serine Augmentation of Neuroplasticity
NCT03711500
Safety and Effectiveness of D-serine in Schizophrenia
NCT00322023
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drug and control CRT
D-serine/control
D-serine
D-serine (30 mg/kg)
Cognitive Retraining Placebo
Cognitive retraining therapy (CRT) control
Drug and CRT
D-serine/cog rehab
D-serine
D-serine (30 mg/kg)
Cognitive Retraining (CRT)
Cognitive retraining therapy (CRT)
Placebo Drug and Placebo CRT
Placebo/control
Placebo
Placebo D-serine Drug
Cognitive Retraining Placebo
Cognitive retraining therapy (CRT) control
Placebo Drug and CRT
Placebo/cog rehab
Cognitive Retraining (CRT)
Cognitive retraining therapy (CRT)
Placebo
Placebo D-serine Drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-serine
D-serine (30 mg/kg)
Cognitive Retraining (CRT)
Cognitive retraining therapy (CRT)
Placebo
Placebo D-serine Drug
Cognitive Retraining Placebo
Cognitive retraining therapy (CRT) control
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion
* Pregnant or lactating
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Alliance for Research on Schizophrenia and Depression
OTHER
Donaghue Medical Research Foundation
OTHER
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Deepak C. D'Souza
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Deepak C D'Souza, M.D.
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Connecticut Mental Health Center
New Haven, Connecticut, United States
VA Connecticut Healthcare System
West Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 1999 Nov;156(11):1822-5. doi: 10.1176/ajp.156.11.1822.
Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998 Dec 1;44(11):1081-9. doi: 10.1016/s0006-3223(98)00279-0.
Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005 Mar 15;57(6):577-85. doi: 10.1016/j.biopsych.2004.12.037.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DF01-015
Identifier Type: -
Identifier Source: secondary_id
23594
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.